TY - JOUR
T1 - Skin autofluorescence, a marker for advanced glycation end product accumulation, is associated with arterial stiffness in patients with end-stage renal disease
AU - Ueno, Hiroki
AU - Koyama, Hidenori
AU - Tanaka, Shinji
AU - Fukumoto, Shinya
AU - Shinohara, Kayo
AU - Shoji, Tetsuo
AU - Emoto, Masanori
AU - Tahara, Hideki
AU - Kakiya, Ryusuke
AU - Tabata, Tsutomu
AU - Miyata, Toshio
AU - Nishizawa, Yoshiki
N1 - Funding Information:
This work was supported by a Grant-in-Aid for Scientific Research (17590946 to HK) from the Japan Society for the Promotion of Science and by a grant from the Osaka Kidney Foundation (OKF06-0007 to HK).
PY - 2008/10
Y1 - 2008/10
N2 - Elevated cardiovascular mortality has been shown to be associated with increased arterial stiffness. However, the contribution of tissue accumulation of advanced glycation end products (AGEs) to increased arterial stiffness is unclear. We examined whether skin autofluorescence, a recently developed marker of tissue accumulation of AGEs, is associated with arterial stiffness in 120 Japanese patients with end-stage renal disease (ESRD) and 110 age- and sex-matched control subjects. The ESRD patients had significantly higher pulse wave velocity (PWV), a noninvasive measure of arterial stiffness, and skin autofluorescence than the control subjects. Skin autofluorescence was significantly associated with age in the group of all subjects (Rs = 0.255, Spearman rank correlation test) and that of control subjects (Rs = 0.493), but not in the group of ESRD subjects (Rs = 0.046). The PWV was significantly and positively associated with skin autofluorescence in the group of all subjects (Rs = 0.335), controls (Rs = 0.246), and ESRD subjects (Rs = 0.205). Multiple regression analyses showed that, in the group of all subjects, association of skin autofluorescence with PWV was significant even after adjustment for other covariates including the presence of ESRD and age. Moreover, for ESRD subjects, a significant association between skin autofluorescence and PWV was found, independent of age. Our findings demonstrate the potential usefulness of skin autofluorescence in people of color and demonstrate clinically for the first time the potential involvement of tissue accumulation of AGEs in the pathophysiology of arterial stiffness.
AB - Elevated cardiovascular mortality has been shown to be associated with increased arterial stiffness. However, the contribution of tissue accumulation of advanced glycation end products (AGEs) to increased arterial stiffness is unclear. We examined whether skin autofluorescence, a recently developed marker of tissue accumulation of AGEs, is associated with arterial stiffness in 120 Japanese patients with end-stage renal disease (ESRD) and 110 age- and sex-matched control subjects. The ESRD patients had significantly higher pulse wave velocity (PWV), a noninvasive measure of arterial stiffness, and skin autofluorescence than the control subjects. Skin autofluorescence was significantly associated with age in the group of all subjects (Rs = 0.255, Spearman rank correlation test) and that of control subjects (Rs = 0.493), but not in the group of ESRD subjects (Rs = 0.046). The PWV was significantly and positively associated with skin autofluorescence in the group of all subjects (Rs = 0.335), controls (Rs = 0.246), and ESRD subjects (Rs = 0.205). Multiple regression analyses showed that, in the group of all subjects, association of skin autofluorescence with PWV was significant even after adjustment for other covariates including the presence of ESRD and age. Moreover, for ESRD subjects, a significant association between skin autofluorescence and PWV was found, independent of age. Our findings demonstrate the potential usefulness of skin autofluorescence in people of color and demonstrate clinically for the first time the potential involvement of tissue accumulation of AGEs in the pathophysiology of arterial stiffness.
UR - http://www.scopus.com/inward/record.url?scp=51649086086&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=51649086086&partnerID=8YFLogxK
U2 - 10.1016/j.metabol.2008.05.016
DO - 10.1016/j.metabol.2008.05.016
M3 - Article
C2 - 18803952
AN - SCOPUS:51649086086
SN - 0026-0495
VL - 57
SP - 1452
EP - 1457
JO - Metabolism: Clinical and Experimental
JF - Metabolism: Clinical and Experimental
IS - 10
ER -